PPT-TRK fusion-positive cancer highlights from ASCO 2022

Prof David S Hong Medical Oncologist MD Anderson Cancer Center Houston TX USA JUNE 2022 2 Please note Views expressed within this presentation are the personal opinions of the author They do not necessarily represent the views of the authors academic institution or the rest of . . Highlights from the Annual Clinical Meeting. Gynecologic Cancer. Sidney A. Scudder, MD. Professor of Medicine. U.C. Davis Cancer Center. Conference Directors:. Helen Chew, MD, FACP. Primo Lara, Jr., MD. Clinical Practice Guideline Update. American Society of Clinical Oncology /. College of American Pathologists . www.asco.org/guidelines/. © American . Society of Clinical Oncology®.  All rights reserved.. Joyce O'Shaughnessy, MD. Kimberly Blackwell, MD. Hope . Rugo. , MD. Reminder: feedback is appreciated. You will be prompted at the end for your feedback.. Updates on Chemotherapy and Other Novel Agents. Clinical Practice Guideline Update. American Society of Clinical Oncology /. College of American Pathologists . www.asco.org/guidelines/. © American . Society of Clinical Oncology®.  All rights reserved.. ASCO-CAP Recommendations For HER2 Testing in Breast Cancer. Criteria For Reporting HER2 Test Results . as Positive. Criteria for Reporting HER2 Test Results . as Negative. Criteria for Reporting Equivocal Results . Mohammad . Jahanzeb. , MD, FACP. Professor of Clinical Medicine, Hematology-Oncology. Director, UM Sylvester Deerfield Campus. Associate Center Director for Community Outreach. Sylvester Comprehensive Cancer Center. Nelson Teng, M.D., Ph.D.. Director, Gynecologic Oncology. Stanford University School of Medicine. Disclosures. I do not have any conflict of interest to report. Acknowledgement. Dr. . Jakob. . Dupont. Eur J Breast Health 2017; 13: 168-74 ABSTRACTBreast cancer is a heterogeneous disease. e purpose of adjuvant therapy for early-stage breast cancer is to provide maximum benet with minimum si Texas Cancer Registry. Texas Department of State Health Services. Agenda – July 7, 2022. General Updates. July 2022 Organizational Chart. Proposed Rules Change. BACKGROUND AND PURPOSE. The purpose of the proposal is to make amendments that will allow for greater flexibility in Texas Cancer Registry data request requirements. Current rule language requires researchers to obtain approval from the DSHS Institutional Review Board (IRB). However, most state cancer registries participate in the federal National Cancer Institute’s Virtual Pooled Registry (VPR) IRB, which allows researchers to use a single IRB to request cancer registry data from multiple jurisdictions. The proposed amendments will allow researchers to submit their study and obtain approval from either the VPR IRB or the DSHS IRB. Researchers with studies that do not meet the requirements for submission to the VPR IRB would still be required to submit their study for review and approval through the DSHS IRB. The proposal also amends current rule language to update the DSHS Texas Cancer Registry email address and make other clarifying, non-substantive changes. . General contact: acsforchange@gmail.com. www.acs-ccu.org. Mandarin Cancer survivor network - Monthly, Online. . Youth Ambassador Program, Monthly, Online. Youth Health Multimedia Contest - Jun 1 to September 17, 2022, online. NSCLC. An update. Solange Peters, MD-PhD. Oncology. . Department. CHUV Lausanne. “In any trial you get the odd patient who does very well, but this is an order of magnitude above that.”. , Mick Peake, . Chemotherapy Alone for Unresectable . Locally Advanced Pancreatic Cancer . Supported by educational grants from AstraZeneca, Bristol Myers Squibb, and Daiichi Sankyo, Inc.. CCO Independent Conference Highlights*. Osp. . Pertini-S.Eugenio-CTO. Therapeutic. . approach. . to. . HER 2 . breast. . cancer. . in . metastatic. . setting. Lisa Carey, SABCS 2018. La malattia HER2 positiva: . Trastuzumab. Key Phase III HER2 Positive MBC Trials. Outlook for cancer care. 01. Gynecologic. Breast. Melanomas of the skin. Brain and other nervous system. Estimates are based on historical incidence rates from the CDC’s United States Cancer Statistics database..